ABOUT
Breaking Through Barriers in Cancer Treatment
Many of today’s cancer drugs fail because they can’t reach their target. Lumigen is pioneering antibody-guided nanocomplexes engineered to overcome the biological barriers that prevent today’s drugs from reaching aggressive tumors.
Born from more than a decade of NIH-supported research, Lumigen’s technology has been validated in NCI’s Nanotechnology Characterization Laboratory and is protected by issued U.S. and EU patents.
Lumigen is advancing toward IND-enabling studies for its lead program, LUM-001, while expanding the NOVVA™ platform into new targets and partnerships.
Leadership
A leadership team with deep experience translating science to commercial success.
Deanne Randolph, MBA
CEO and Founder
Daniel Bednarik, PhD
Interim Chief Science Officer
Haifeng Liang, MBA
Financial Advisor
Dana Dunn, MS
Regulatory Advisor
Nathalie Riebel, MBA
Clinical Advisor
Board of Directors
Jeffrey Hausfeld, MD, MBA
Chairman of the Board
Deanne Randolph, MBA
CEO and Founder
Inventors and Scientific Advisors
Our advisors include the University of Maryland inventors of the NOVVA™ platform, renowned leaders in neurosurgery, molecular biology, and nanomedicine, providing unmatched scientific continuity and translational insight.
Anthony J. Kim, PhD
Jeffrey A. Winkles, PhD
Graeme F. Woodworth, MD